Charles River Laboratories International’s (CRL) Hold Rating Reiterated at Argus

Argus reissued their hold rating on shares of Charles River Laboratories International (NYSE:CRL) in a report released on Friday morning, MarketBeat Ratings reports.

Other analysts also recently issued reports about the company. Robert W. Baird lowered their price objective on Charles River Laboratories International from $282.00 to $270.00 and set an outperform rating for the company in a research note on Friday, May 10th. StockNews.com cut Charles River Laboratories International from a buy rating to a hold rating in a research note on Friday, June 14th. The Goldman Sachs Group started coverage on shares of Charles River Laboratories International in a research note on Thursday, June 6th. They issued a buy rating and a $290.00 target price for the company. Mizuho assumed coverage on shares of Charles River Laboratories International in a research report on Friday, June 7th. They set a neutral rating and a $235.00 price target on the stock. Finally, TheStreet raised shares of Charles River Laboratories International from a c+ rating to a b- rating in a research report on Friday, March 1st. Eight equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of Hold and a consensus target price of $254.50.

Charles River Laboratories International Price Performance

Shares of CRL opened at $206.58 on Friday. The stock has a market cap of $10.64 billion, a P/E ratio of 24.30, a P/E/G ratio of 1.95 and a beta of 1.40. The business’s fifty day moving average is $220.16 and its 200 day moving average is $232.74. The company has a quick ratio of 1.37, a current ratio of 1.75 and a debt-to-equity ratio of 0.73. Charles River Laboratories International has a 12-month low of $161.65 and a 12-month high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Thursday, May 9th. The medical research company reported $2.27 earnings per share for the quarter, beating analysts’ consensus estimates of $2.05 by $0.22. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $997.24 million. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. Sell-side analysts anticipate that Charles River Laboratories International will post 11 earnings per share for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 1,304 shares of Charles River Laboratories International stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $226.97, for a total value of $295,968.88. Following the completion of the sale, the executive vice president now owns 23,276 shares of the company’s stock, valued at approximately $5,282,953.72. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 1.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Norges Bank bought a new position in shares of Charles River Laboratories International in the fourth quarter worth $101,319,000. Point72 Asset Management L.P. boosted its stake in Charles River Laboratories International by 499.1% in the 4th quarter. Point72 Asset Management L.P. now owns 368,984 shares of the medical research company’s stock worth $87,228,000 after purchasing an additional 307,398 shares during the period. Meritage Group LP grew its holdings in Charles River Laboratories International by 30.8% during the 4th quarter. Meritage Group LP now owns 1,155,376 shares of the medical research company’s stock valued at $273,131,000 after buying an additional 271,743 shares in the last quarter. Epoch Investment Partners Inc. increased its position in shares of Charles River Laboratories International by 2,733.4% during the first quarter. Epoch Investment Partners Inc. now owns 247,501 shares of the medical research company’s stock valued at $67,060,000 after buying an additional 238,766 shares during the period. Finally, KBC Group NV lifted its holdings in shares of Charles River Laboratories International by 5,003.9% in the fourth quarter. KBC Group NV now owns 215,639 shares of the medical research company’s stock worth $50,977,000 after buying an additional 211,414 shares in the last quarter. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).